Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
about
EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcomaCrystal structure of the BTB domain from PLZFSequestration and inhibition of Daxx-mediated transcriptional repression by PMLIdentification of mammalian Sds3 as an integral component of the Sin3/histone deacetylase corepressor complex.The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger proteinmSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factorNuclear receptor corepressorsArsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemiaOligomerization of ETO is obligatory for corepressor interactionThe zinc finger-associated SCAN box is a conserved oligomerization domainProteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZFGenomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger geneThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyRole of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and CancerRetinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsValproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsMonocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cellsDNA replication progresses on the periphery of nuclear aggregates formed by the BCL6 transcription factorCuring all patients with acute promyelocytic leukemia: are we there yet?Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein.Histone deacetylase 1 can repress transcription by binding to Sp1.In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions.Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemiaAberrant corepressor interactions implicated in PML-RAR(alpha) and PLZF-RAR(alpha) leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants.Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression.The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networksThe promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytes8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation.Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins.Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation.Regulation of epithelial sodium transport by promyelocytic leukemia zinc finger protein.RARα-PLZF oncogene inhibits C/EBPα function in myeloid cells.Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalphaThe epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells.Regulation of hematopoietic development by ZBTB transcription factors.
P2860
Q21144325-E8059327-1FE5-4B6B-B312-6BE17DED7FE8Q22003945-0CEE6706-E718-423F-B6E2-39641667247FQ22253162-EE43BAE2-4892-4343-9F2F-CA7C92FE354BQ24292515-64C981EA-4A46-4B21-93CF-E7EDC7A5BBC0Q24523980-18D9F66F-46F6-4297-95D2-9B60E349F586Q24524018-F19CCAF9-0D04-428F-99F4-245F69870607Q24540376-EB7B13A6-95C1-475E-B1DE-BF03CD0BB6ACQ24548302-A36AAA46-AA40-4300-8F60-24FC7298F67DQ24550754-A166209E-FDA1-4991-93F4-6BB1E16640D4Q24554375-7DE1F276-ED3B-4CCB-A1DD-3C14019F5F45Q24672346-01FA894D-49E6-4ED3-835B-A0E9FCBEF1EFQ24685762-9D2C8BB7-D3D4-4393-9125-3E801FA4F52CQ26799596-C648298F-941E-48D7-8034-D53A699F61E5Q26800202-3AA54AC2-0887-4CEA-B777-D03C0D0942E9Q28344657-AB8517B2-3FB8-49C7-BA6D-010AF0395D59Q28366303-6DB385A4-482C-456B-A3FD-C8964CEEF790Q28590949-CE8B9ED1-36FF-4526-BB5A-C2E0ED0DC11FQ30949530-CC256481-73F1-4234-B8B7-49A824350904Q33613426-37455920-A36B-40FE-8385-084250245CC6Q33863009-10E57F1C-0133-4555-A00C-7C7B24C0EA24Q33958899-127A017D-1F7F-4B81-86EA-77BC7E920880Q33965235-11744F83-12AC-4271-B3F6-4752B3AFC11CQ34064907-E2A33395-BE5A-4C5F-A4D5-2F2303FF7A02Q34324111-E1D48DDD-70CF-4180-BDA7-B71471B8F613Q34340593-A9ACF226-AFCD-4502-8DAD-96186E139E31Q34575940-CEEDD9C1-091F-4A4A-95CE-68F84A715FF6Q34889102-68B15BD5-4E21-4F95-831A-32FF4BC50CC4Q35160462-525BA2ED-3E55-44E2-8379-4FC8806B4AB0Q35879576-B778062B-92E9-4D36-AE9E-B335EC76A6FAQ36276965-3D009530-2611-434E-979E-B6C8FEF8B422Q36570690-B4CB72FC-F4EE-46A9-9BB0-C2C2DD3C2DB2Q36603944-9B3A2EA2-A91D-4F4F-9106-DEE52B2E2348Q36653805-FB5D51A4-A314-4BEB-859C-38C18FBD75D9Q36774571-FF5EFA43-0B2C-4169-9DE9-5989000A12D0Q36790219-CF8BE3C4-1DB1-421A-B88D-6EF39897CEFEQ36807133-E9B6C450-3894-45A6-8C5F-60F0D227FD92Q37103871-26BA644C-27F4-4F0E-87C6-EBD4E0D9B317Q37206203-18D4AF00-1810-46CA-BAE2-FDFC0B1B80ACQ37261517-8F624ED3-8FD3-4C49-8670-43D75D100E30Q38850477-BE4244AD-BE54-4B16-B7DE-6F6A8378261D
P2860
Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@ast
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@en
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@nl
type
label
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@ast
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@en
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@nl
prefLabel
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@ast
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@en
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@nl
P2093
P1433
P1476
Reduced retinoic acid-sensitiv ...... f acute promyelocytic leukemia
@en
P2093
P304
P407
P577
1998-04-15T00:00:00Z